Oragenics Inc. (NYSE American: OGEN) provided a shareholder update on Monday, highlighting progress in its Phase IIa clinical trial of ONP-002 for concussion and mild traumatic brain injury (mTBI). The company reported active patient enrollment and dosing underway across multiple sites in Australia, while advancing U.S. regulatory preparations. Oragenics is targeting a Type C FDA meeting request in the second quarter of 2025 and an Investigational New Drug (IND) submission by year-end 2026.
The company also disclosed a letter of intent to pursue licensing of a complementary CNS-related medical device, signaling a strategic expansion into broader neurological care. This move aligns with Oragenics' focus on brain-targeted therapeutics through its proprietary intranasal delivery technology. The company's lead candidate, ONP-002, is being developed as a potential first-in-class treatment for concussion and mTBI, conditions with significant unmet medical needs.
Oragenics reported a March 31, 2025, cash balance of $6.1 million, providing a runway to support ongoing clinical activities. The company's intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. For more details, the full press release is available at https://ibn.fm/tEk2C.
The Phase IIa trial in Australia is a critical step toward demonstrating safety and efficacy of ONP-002, with U.S. Phase 2b trials planned to follow. Oragenics is committed to developing innovative therapies that address significant unmet medical needs in neurological care. Investors can find the latest news and updates at https://ibn.fm/OGEN.
Oragenics is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The company's efforts are focused on advancing ONP-002 as a potential first-in-class treatment for concussion and mild traumatic brain injury. With a strong pipeline and strategic initiatives, Oragenics aims to make a significant impact in neurological care.